This drug improves kidney function, obesity, and HFpEF outcomes, thus improving all 3 elements that interact to create this syndrome. 1 About the Trial Trial Name: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial ClinicalTrials.gov ID: NCT04847557 Sponsor: Eli Lilly and Company Completion Date: July 2, 2024 The presence or absence of CKD did not impact the frequency of gastrointestinal symptoms in the 2 treatment groups, according to the investigators
Why Thibodaux Patients Choose MOPE Over Online Clinics Chris Rue, APRN, FNP-C has been on testosterone replacement therapy his entire adult life
Hepatorenal and cerebellar anti-toxic effects of curcumin against orlistat associated toxicity in obese male albino rats
Some digital models record minimum and maximum temperatures, which provides exact data about how warm the fridge got during an outage
pmid:19056485 21
Patients experiencing severe, persistent abdominal pain (with or without vomiting) should stop tirzepatide immediately and seek urgent medical evaluation to rule out pancreatitis